15 / 15
allied
academies
Virology Research Journal
Volume 1 Issue 4
Vaccines World 2017
Notes:
Page 32
November 09-10, 2017 Vienna, Austria
21
st
World Congress and Exhibition on
VACCINES, VACCINATION & IMMUNIZATION
Successfully activating positive behaviors of the
stakeholders involved in vaccine purchasing and
usage through technological advances
Pierre A Morgon
1,2
1
MRGN Advisors, Switzerland
2
Virometix, Switzerland
T
he vaccine segment is anticipated to be one of the fastest
growing one of the healthcare industry and several
leading firms have stepped up vaccine investments in recent
years. Unlike therapeutic agents, vaccines are administered
to healthy individuals only once or very infrequently during
a life time. Vaccines generate well-documented positive
externalities, yet their poor awareness and acceptability
among vaccine end-users may contribute to resurgence of
transmissible diseases and consequently trigger governmental
interventions such as mandating vaccination. In addition to
technical and clinical development as per the highest quality
standards, bringing new vaccines to market requires carefully
orchestrated programs targeting the multiple types of
stakeholders along the entire value chain and addressing their
respective purchasing behavioral drivers. Against a backdrop
of anti-vaccination buzz and vaccine fatigue, successful
global launch and sustainable usage of a vaccine requires
the development of a multi-pronged strategy addressing all
aspects in relation to acceptability (e.g. the motivation to
immunize despite the quasi-disappearance of the disease),
accessibility (e.g. supply chain services), availability (e.g.
mechanisms ensuring reliability of supply) and affordability
(e.g. tiered pricing policy taking country differences in per
capita income into account). Leveraging novel technological
advances can positively influence the ability to activate these
levers successfully.
Biography
Pierre A Morgon is Chief Executive Officer of MRGN Advisors, a consultancy
dedicated to the healthcare sector, and Regional Partner for Switzerland
at Mérieux Développement, an evergreen investment structure focused on
medical devices,
in vitro
diagnostics and patient management services. He is
also holding the following board positions: Chairman of the Board of Virometix,
a company developing proprietary synthetic nanoparticle platform in vaccines
and immunotherapeutic drugs for viral diseases and cancer; Non-Executive
Director to the Board of Theradiag, a company focusing on in vitro diagnostics
in auto-immunity, infectious diseases and allergy; Non-Executive Director to the
Board of Eurocine Vaccines, a company dedicated to developing intra nasal
vaccines. He holds a Doctorate of Pharmacy, a Master in Business Law and a
MBA. He is also an alumnus of INSEAD, IMD and MCE executive programs.
pm@mrgnadvisors.comPierre A Morgon, Virol Res J 2017, 1:4